Does hyperprolactinemia treatment affect pregnancy and perinatal outcomes?

Area of Science:

• Endocrinology
• Obstetrics & Gynecology
• Reproductive Medicine

Background:

• Hyperprolactinemia, a condition characterized by elevated prolactin levels, can affect reproductive health.
• Dopamine agonists, such as cabergoline and bromocriptine, are commonly used to treat hyperprolactinemia.
• Understanding the impact of different treatments on pregnancy outcomes is crucial for patient management.

Purpose of the Study:

• To compare obstetric and perinatal outcomes in pregnant women with hyperprolactinemia based on their treatment with cabergoline or bromocriptine.
• To determine if the type of dopamine agonist used influences pregnancy complications or delivery outcomes.

Main Methods:

• A retrospective cohort study included 464 women diagnosed with hyperprolactinemia treated with dopamine agonists.
• Pregnant women (n=72) were divided into groups based on treatment: bromocriptine or cabergoline.
• Obstetric and perinatal outcomes, including pregnancy and intrapartum complications, were evaluated.

Main Results:

• No significant differences in obstetric outcomes were observed between women treated with bromocriptine versus cabergoline.
• The majority of women experienced uncomplicated pregnancies (76.3%) and intrapartum periods (86.8%).
• Idiopathic hyperprolactinemia was more frequently treated with bromocriptine, while tumoral hyperprolactinemia was more often treated with cabergoline (p=0.04).

Conclusions:

• Hyperprolactinemia does not appear to negatively impact obstetric outcomes in pregnant women.
• The type of prior dopamine agonist treatment (cabergoline or bromocriptine) did not alter pregnancy or delivery outcomes.